Cognition Therapeutics Inc
CGTX
Company Profile
Business description
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Contact
2500 Westchester Avenue
PurchaseNY10577
USAT: +1 412 481-2210
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,768.60 | 1.60 | -0.02% |
| CAC 40 | 7,790.27 | 14.40 | -0.18% |
| DAX 40 | 24,323.58 | 47.10 | 0.19% |
| Dow JONES (US) | 42,319.74 | 108.00 | -0.25% |
| FTSE 100 | 8,811.04 | 9.75 | 0.11% |
| HKSE | 23,906.97 | 252.94 | 1.07% |
| NASDAQ | 19,298.45 | 162.04 | -0.83% |
| Nikkei 225 | 37,611.82 | 57.33 | 0.15% |
| NZX 50 Index | 12,596.76 | 19.61 | 0.16% |
| S&P 500 | 5,939.30 | 31.51 | -0.53% |
| S&P/ASX 200 | 8,538.90 | 2.90 | -0.03% |
| SSE Composite Index | 3,384.10 | 7.90 | 0.23% |